CONTENTS 317 E 2012 BPSD 31 v BPSD i BPSD d BPSD e n c e
|
|
|
- けんじ みつだ
- 7 years ago
- Views:
Transcription
1
2 CONTENTS 317 E 2012 BPSD 31 v BPSD i BPSD d BPSD e n c e
3 2012. Vol.36 No.2 28 Science of Kampo View Papers Clinical Research OAB Change in cytokine levels after administration of saikokaryuukotsuboreito or testosterone in patients with symptoms of late-onset hypogonadism Case Report Conference Report PSJM Information
4 2012 BPSD 31 BPSD AD 3 1
5 31 Asada Takashi J-ADNI AD AD mild cognitive impairment MCI MCIpreclinical β Aβ 2 AD J-ADNI Japanese Alzheimer s disease neuroimaging initiative ADNI AD Aβ 1 AD MRI J-ADNI MRI PET PET Aβ AD MCI 300 AD AD
6 2012 BPSD 2 A preclinical Sperling RA, et al Alzheimers Dement. 2011, 7(3), p AD AD 4 AD ACh 3ACh AChE AD ACh ACh AChE ACh ACh 4AChE ACh BuChE 5 2
7 3 ACh AChEACh ACh 4 AChE ACh ACh ACh ACh 3 NMDA N-methyl- D-aspartate 6 NMDA 1 AD Aβ NMDA Ca 2 NMDA Ca AD
8 2012 BPSD 5 AChE BuChE BuChE ADAChE BuChE BuChE ACh 6 1 NMDA N-methyl-D-aspartate AD A NMDA Ca 2 NMDA Ca 2 MCI
9 2008 BPSD QOL BPSD BPSD BPSD BPSD 2
10 2012 BPSD BPSD BPSD BPSD 7 BPSD 7 BPSD 2009, 20 p QOL
11 2012 BPSD BPSD 2011 BPSD BPSD BPSD BPSD BPSD BPSD 1 5-HT ACh DA NA Glu AD BPSD 2 AD ACh ACh AChE ACh AChE-I AD AChE-I 3 BPSD2005
12 2012 BPSD Endo Hidetoshi 2011 BPSD Glu Glu BPSD Glu Glu Glu Glu Glu Glu Glu Glu AD Glu Glu GluNMDA AD β 1 BPSD Glu NMDAGlu NMDA Ca 2 BPSD Glu * NMDA ND NMDA AMPA α NMDA Ca 2 Ca 2 Merz NMDA 5-HT CA1 BPSD 2005
13 Glu NMDA NMDA AD Glu NMDA Ca 2 Ca 2 Ca 2 Glu BPSD ** Glu NMDA 2 DA NA 5-HT Glu ChAT ACh ACh DA AD 25 DA NA NA 5-HT AD 5-HT 5-HT Glu Glu Glu BPSD BPSD Glu Glu Glu Glu Glu Glu 5-HT 5-HT5-HT1A 5-HT2A ***
14 2012 BPSD 1 BPSD BPSD BPSD BPSD BPSD Glu 5-HT 2 3 Glu 1 Glu NMDA Ca 2 Glu Glu Glu Glu Ca 2 Glu NMDA NMDA Glu
15 2 BPSD , 34 2, p Glu NMDA NMDA 5-HT BPSD HT 5-HT 1A 5-HT 5-HT 1 5-HT 2A 5-HT 2A 5-HT 2A BPSD BPSD BPSD Glu
16 2012 BPSD 3 BPSD Takeda A, et al. Nutr Neurosci. 2008, 11 1, p Takeda A, et al. Neurochem Int. 2008, 53, p Kawakami Z, et al. Neuroscience. 2009, 159 4, p Kawakami Z, et al. Eur J Pharmacol. 2010, 626, p Terawaki K, et al. J Ethnopharmacol. 2010, 127, p Egashira N, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2008, 32, p NMDA 2010 BPSD DLBNPI NPI BPSD BPSD 4 BPSD BPSD 3
17 2012 BPSD BPSD BPSD BPSD BPSD , , AD DLB/PDD MCI VaD MCI 3 AD DLB VaD 1 * AD β Aβ AD 80 90
18 2012 BPSD Okahara Kazunori BPSD BPSD AD BPSD ADL FDA
19 ADL 1 ADL BPSD BPSD 1 AD DLB VaD 2 AD BPSD 85 MCI BPSD Glu BPSD Glu Glu BPSD Glu 5-HT 5-HT 2A 5-HT 1A BPSD Glu Glu Glu Glu BPSD ADL Glu BPSD 2
20 2012 BPSD AChE-I AD AChE-I BPSD 3 BPSD DLB AChE-I L-dopa 4 BPSD 2 5-HT 558 BPSD AD 124 DLB 23 VaD NPI ZBI BPSD
21 NPI 3 meq/l NPI ZBI BPSD 1 ** NPI neuropsychiatric inventory *** ZBI Zarit caregiver burden interview DLB 5 NPI ZBI Okahara I.American Psychiatric Association, 2011 Annual Meeting
22 2012 BPSD BPSD 3 AChE-I NMDA BPSD Glu 6 n=150 Okahara I. American Psychiatric Association, 2011 Annual Meeting 7 n=163 Okahara I. American Psychiatric Association, 2011 Annual Meeting BPSD mg 15 mg 20 mg 2 BPSD
23 2012 BPSD BPSD BPSDBPSD 2005FDA BPSD BPSD 2003 BPSD BPSD BPSD BPSD 1 BPSD 1 BPSD FDA 2 BPSD RCT BPSD ADL 3 BPSD ADL RCT BPSD
24 2012 BPSD Arai Hiroyuki Barthel Index p 0.05 MMSE g 3 5.0g 2 ADL BPSD 1 BPSD 1 DLB BPSD DLB DLB NPI p= NPI p BPSD BPSD 25 mg 4 NPI p NPI 2- ADL 1 ZBI NPI Tanji H, et al. Geriatr Gerontol Int. 2005, 5, p.94-98
25 Barthel Index MMSE DLB 63 4 NPINPI p Zarit Burden Interview ZBI p= MMSE DLB BPSD 2- NPI Iwasaki K, et al. J Clin Psychiatry. 2005, 66(2), p p 0.05 p = NPI Iwasaki K, et al. J Clin Psychiatry. 2005, 66(2), p
26 2012 BPSD 1 BPSD Iwasaki 3 AD VaD DLB RCT 52 vs 4 NPIp NPI Barthel Index p 0.05 MMSE 2 7.5g 5g Iwasaki 4 DLB 15 4 NPIp= NPI p Barthel Index p= MMSE Mizukami 5 AD DLB RCT Arm1 Arm2 4 NPIArm1 p=0.002 Arm2 p= NPI Arm14 Arm24 MMSE IADL Barthel Index Monji 6 AD 15 RCT 2 vs 12 NPI8 12 p=0.001 MMSE Barthel Index 2 1 p=0.141 Okahara 7 AD 63 RCT 4 vs 4 NPIp 0.05 NPI p 0.05 MMSE DAD SDS ZBI Hayashi 8 Iwasaki 9 BPSD 80% AD 26 DLB 63 4 NPIp= NPI p 0.05 MMSE DAD SDS ZBI NPIp NPI p ZBI MMSE ADVaD DLB IADL Barthel Index DAD ADLSDS ZBI ( )
27 3 NPI ZBI MMSE Iwasaki K, et al. J Am Geriatr Soc. 2011, 59(5), p NPI Mizukami K, et al. Int J Neuropsychopharmacol. 2009, 12, p AD DLB Arm1 4 4 Arm2 ADL instrumental activities of dairy living scale IADL Barthel Index 4 NPI Arm1 p=0.002 Arm2 p= Arm1 NPI 1
28 2012 BPSD NPI Arm1 Arm2 MMSE Barthel Index IADL IADL ADL 8 IADL NPI Monji A, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2009, 33, p NPI 6 AD 15 n=10 n= mg 4 NPI mg 6 Monji A, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2009, 33, p mg NPI 8 12 p Barthel Index MMSE mg 100
29 mg 6 BPSD BPSD 7 NPI Okahara K, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34, p NPI 1 4 AD NPI p NPI p NPI Okahara K, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34, p MMSE DAD BPSD BPSD 80
30 2012 BPSD AD NPI p= NPI p 0.05 MMSE DAD ZBI 1 1 BPSD AD ADLBPSD BPSD 2009 AD BPSD TEL FAX harai@idac.tohoku.ac.jp 1 Tanji H, et al. Geriatr Gerontol Int. 2005, 5, p Schneider LS, et al. JAMA. 2005, 294, p Iwasaki K, et al. J Clin Psychiatry. 2005, 66(2), p Iwasaki K, et al. J Clin Psychiatry. 2005, 66(12), p Mizukami K, et al. Int J Neuropsychopharmacol. 2009, 12, p Monji A, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2009, 33, p Okahara K, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34, p Hayashi Y, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34, p Iwasaki K, et al. J Am Geriatr Soc. 2011, 59(5), p
31 2012 BPSD %
32 2012 BPSD BPSD ,800
33 1 BPSD 2 BPSD BPSD
34 2012 BPSD 2011 NMDA 3 2
35 BPSD BPSD AD 2 AD BPSD mg/ g g 2 2 1
36 2012 BPSD BPSD
37 2012 BPSD BPSD ISO ,
38 2012 BPSD MRI AD VaD 500 DLB AD MRI CT 3 4
39 BPSD AD VaD DLB 3 3 AD HDS-R MMSE HDS-R 20 MMSE23 3 CT MRI BPSD BPSD BPSD 1 BPSD BPSD 1 3
40 2012 BPSD 4 BPSD BPSD BPSD AD 3 DLB DLB AD MRI AD 7.5 g AD 2 68 DLB 2.5 g DLB
41 P BPSD HDS-R 20 MRI VSRAD=2.05 AD g 2 68 DLB 1 HDS-R 24 MRI DLB 2.5 g BPSD
42 2012 BPSD BPSD BPSD JA ) BPSD 2
43 hydroxysteroid dehydrogenase type2 K + K + BPSD ) ) BPSD
44 2012 BPSD Mantani Akio BPSD ADL BPSD 1 471Da 99 3 Ishida 1989 open label study 4) 11 8 VaD 3 MMSE Mini-mental State Examination g
45 3 4 BPSD BPSD NPI Bathel index 10 Bathel index 10 NPI ADL MMSE20 DSM- TR g 3 4 NPIBathel index NPI NPI 1 1 ADLBathel index BPSD ADL 4 NPI p= p= p=0.0173) Bathel index ADL meq/l meq/l 6 BPSD
46 2012 BPSD 4 NPI n 11 Mantani A, et al.am J Geriatr Psychiatry, 2011, 19(10), p BPSD ADL BPSD NPI 5 Bathel index n 11 Mantani A, et al.am J Geriatr Psychiatry, 2011, 19(10), p n 11 Mantani A, et al.am J Geriatr Psychiatry, 2011, 19(10), p ) 2010, 63, p ) , 45(1), p ) Fukunishi I, Kitaoka T, Shirai T, et al. Psychiatric disorders among patients undergoing hemodialysis therapy. Nephron. 2002, 91, p ) Sumiyoshi H, Mantani A, Nishiyama S, et al. Yokukansan treatment in chronic renal failure patients with dementia receiving hemodialysis: an open label study Am J Geriatr Psychiatry. 2011, 19(10), p
47 RCT
48 OAB 1 C
49 goshajinkigan DA 5-HT NA P SP OAB dynorphin
50 2 OAB C C Awake ml ml X
51 goshajinkigan 2 3 Neuromodulation 3 C A C 2 3 C-Fos Fos 3 2
52 JR ER
53 DMAT DMAT
54
55
56 8 51.5%
57 QOL 1
58 The Aging Male Change in cytokine levels after administration of saikokaryuukotsuboreito or testosterone in patients with symptoms of late-onset hypogonadism 40 late-onset hypogonadism LOH 31 3 ng/ml g 3 3 ng/ml mg Aging male s symptoms AMS AMS AMS IL-8 IL-13 IFN-γ TNF-α LOH LOH LOH LOH LOH LOH AMS 1 LOH TNF-α IL-6 LOH AMS 40LOH 31 3 ng/ml g / 3 3 ng/ml mg 2 2 AMS 18 IL-1β IL-2 IL-4 IL-5 IL-6 IL-7 IL-8 IL-10 IL-12 IL-13 Il-17 G-CSF GM-CSF IFN-γ MCP-1 MIP-1β TNF-α VEGF AMS AMS AMS AMS
59 1 IL-8 IL-13 IFN-γ TNF-α 1 LOH LOH AMS LOH LOH AMS LOH IL-8 IL-13 IFN-γ TNF-α 1 AMS LOH p AMS p 0.01 AMS p 0.05 AMS p 0.05 AMS NS ng/ml NS pg/ml NS NS pg/ml SD Wilcoxon s rank sum test vs 1 n=15 SD Wilcoxon s rank sum test vs LOH 1 1 Tsujimura A, et al. Aging Male. 2008, 11, p
60 QOL TJ ml 65 ADL TJ g 5 ml g900 ml
61 ,800 ml Davis 2,000 ml ,800 ml ADL m L 4 1 g 900 ml 1 1
62 g 5 ml 900 ml ml ) 4 6) 4 7) p 0.05 χ ml 1,800 ml 8 9) ml 10 11) 2.5 g g ml 900 ml Davis GR, Santa Ana CA, Morawski SG. et al. Development of a lavage solution associated with minimal water and electrolyte absorption or secretion. Gastroenterology. 1980, 78, p ,,,. P , 44(10), p ,, , p , 8(6), p.14. 5, , p , 20(3), p , , p.31. 8,, , 11(10), p ,,,. P , 72(10), p ,,, , 50(4), p ,,,. CS P , 18(1), p , , p
63 20 TJ g ) X CT TJ g ) ) g
64 (2), p ) 1 2
65 4) ) n=20 10) 6) g 3 6 8) )
66 4 1 X a b c d 2 X RS 3 GERD , p H * 7 * 8 * ** * ** , p.41.
67 QOL g p , p.8. 3., , p , p , 140 3, p , 29 2, p , p , p ,,,. Shen-bi-tang:SBT sodium cromoglicate , p , 10 1, p.25.
68 4 10 TEL FAX ,000 4, p CD-ROM MS-word text TEL FAX
69 Ca se Report aquaporin AQP 4 1, 2 aquaporin AQP g / g / CT CT MRI CT 3 modified Rankin Scale mrs mrs 2 1 mrs 3 0 mrs 4 5 mrs
70 Ca se Report 1 3 mrs JCS II-20 MMT 0/5 bruit CT MRI T2 FLAIR 1 10, mg ml 2 TJ g 7.5 g / CT 2 3 mrs JCS III- 100 CT MRI T2 FLAIR MRA M1 3 10, mg ml 2 TJ g 7.5 g / CT 4 mrs malignant cerebral hemispheric stroke malignant middle cerebral artery (MCA) infarction 80 CT MCA 35 50
71 1 1 MRI 2 1 CT CT
72 Ca se Report 3 2 MRI 4 2 CT MRI 50 CT
73 AQP 4 3, 4 AQP 28kDa 5 AQP 1 AQP 4 AQP 4 AQP 4 endfeet AQP 4 AQP 6 9 Manley AQP 4 endfeet AQP 4 10) 1 g/ kg 3 g/kg 3, 4 15 g AQP 4 CT AQP Japan Standard Stroke Registry (JSSRS). J Tradit Med. 2003, 20, p Kampo Med. 2010, 61(1), p , 35(2), p , 17(1), p Hasegawa H, Ma T, Skach W, et al. Molecular cloning of a mer-curialinsensitive water channel expressed in selected water-transporting tissues. J Biol Chem. 1994, 269, p Aquaporin , 29(2), p.31. 7,,,.. Anesthesia 21 Century. 2008, 10(1-30), p Taniguchi M, Yamashita T, Kumura E, et al. Induction of aquaporin-4 water channel mrna after focal cerebral ischemia in rat. Brain Res Mol Brain Res. 2000, 78, p Sato S, Umenishi F, Inamasu G, et al. Expression of water channel mrna following cerebral ischemia. Acta Neurochir Suppl. 2000, 76, p Manley GT, Fujimura M, Ma T, et al. Aquaporin-4 Deletion in mice reduce brain edema after acute water intoxication and ischemic stroke. Nat Med. 2000, 6, p.159.
74 Ca se Report 2 1 TJ-17 TJ-114 2, ,000 2,000 4,000 Hz 5 70 db Grade-3b mg 1,500 μg db MRI g db 9 g db
75 Grade 1 Grade 2 40 db 40 db 60 db ,000 2,000 4,000 Hz 20 db Grade 3 60 db 90 db 5 30 db Grade 4 90 db ,000 2,000 4,000 Hz a b db 5 10 db db 30.0 db db 40 db db Grade 3b mg 1,500 μg 9 g 3
76 Ca se Report 3 1 MRI db db db db db 2
77 db 38.8 db db db db Grade 37 5 E db 2 2
78 Ca se Report MRI B 12 E 1 1 3, 9, 10, ,.. ENTONI. 2005, 54, p.20 2,,, , 79, p JOHNS. 1999, 15, p.319 4,.. ENTONI p.13 5,,,.. Audiology Japan. 2006, 49, p.782 6,,,.. Otol Jpn. 2009, 19, p Audiology Japan. 2009, 52, p Audiology Japan. 2006, 49, p ,. 1. Progress in medicine. 1994, 14, p ,. JOHNS. 2010, 26, p , 19, p , 35, p ENTONI. 2007, 78, p Iwai I, Suda T, Tozawa F, et al. Stimulatory effect of Saireito on proopiomelanocortin gene expression in the rat anterior pituitary gland. Neurosci Lett. 1993, 157 1, p
79 Conference Report webkampo Square Conference Report webkampo Square Conference Report webkampo Square
80 16 PSJM hypoganglionosis Peritoneal inclusion cyst 1 14 CPT in vitro 16 Herbal medicine used in pediatric surgery in China Conference Report webkampo Square
81 I Conference Report webkampo Square Conference Report webkampo Square Conference Report webkampo Square
82 I II FOLFOX FOLFIRI 4FOLFIRI III 1 2 Capecitabine Hand foot syndrome 3 4. Conference Report webkampo Square
83 B p
84
untitled
239 10 3 14 00 14 50 1 : 10 2 10 30 11 30 1 : 10 4 13 00 14 00 1 : 10 2 13 00 14 00 1 : Peter St. George - Hyslop University of Toronto 10 2 14 10 15 10 1 : Randall Bateman Neurology at Washington University
Diagnosis of Dementia: Update
10 C A 1 2 Normal SMI MCI Early Dementia B Moderate Dementia 3 Severe Dementia 4 5 D AD, VD, FTD, DLB, PDD Depression Dementia d/t GMC Modifiable risk factors and preventive factors for dementia 6-5 -
2009年133巻3号3月号.indb
Folia Pharmacol. Jpn.133 1 2 Chiroscience UCB S RR-..% AA C IC C/A A/ A R- II/ III II/III Chiroscience UCB S 1 - E-mail: koji_taya@maruishi-pharm.co.jp Author: Koji Taya, Satoshi Shimizu Title: Levobupivacaine
Medical Journal of Aizawa Hospital Medical Journal of Aizawa Hospital Vol. 8 (2010) Key words Neuropsychopharmacology Neuroscientist Curr Opin Neurol Clin Rehabil J Neurol Neurosurg Psychiatry
imazu.org
2013 9 1512:00~13:00 2F http:// imazu.org 5 1 68 19 54 127 14 17 100 31 http:// imazu.org 1 55 200X S 201X http:// imazu.org 1 55 http:// imazu.org 1 55 http:// imazu.org 75mg/ 1 9g / 21 mg 70 % 14.7 mg
intent-to-treat population, which included all patients who received at least 1 dose of medication at baseline and had at least 1 postbaseline assessm
BPSD に対する抑肝散の効果 (140828) 抑肝散に関する RCT が結構たくさん出ている 実際 BPSD に関しては効果を実感する症例も あると思う いくつかの論文を読んでみた PECO P:BPSD in elderly patients with dementia(ninety inpatients with dementia according to the Diagnostic and
medicaljournal8.pdf
Medical Journal of Aizawa Hospital Vol. 8 (2010) Key words Neuropsychopharmacology Neuroscientist Curr Opin Neurol Clin Rehabil J Neurol Neurosurg Psychiatry J Neurol Neurosurg Psychiatry Lancet
36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: , 要旨 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visi
36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: 378 384, 2014 1 2 要旨 1999 2012 10 31 29 26 80 30 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visit time, chronological change はじめに 4 12 23 27 1 Japan
Systematic Review of Psychological Assessment for elder clients, No. The review about Intelligence or Memory Scale for Dementia Kyoko WATANABE
Systematic Review of Psychological Assessment for elder clients, No. The review about Intelligence or Memory Scale for Dementia Kyoko WATANABE http://www.stat. go.jp. % Mini Mental State Examination MMSE
終末期の呼吸困難症状への対応*松坂最終修正
Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,
プログラム_指定演題.indd
400 Dementia Japan Vol. 27 No. 4 October 2013 11 9 13 45 14 15 1 : 11 9 14 15 15 15 1 : β β Jorge A Ghiso Departments of Pathology and Psychiatry, New York University School of Medicine, New York, USA
BPSD A 群 B 群 A 群 B 群 妄想幻覚興奮うつ不安 n mean S.D. p-value n mean S.D. p-value 0 週 p= p= 週 週
BPSD の治療 Pharmacotherapy for BPSD 筑波大学大学院人間総合科学研究科精神病態医学分野 / 准教授 * 1. はじめに 8 Behavioral psychological symptoms of dementia BPSD 図 1BPSD BPSD BPSD BPSD 2. 興奮 攻撃性の治療 2005 図 2 DLB K BPSD 図 3 心理症状 幻覚 ( 幻視
Clinical Study of Effect of Intrathecal Use of Alpha-tocopherol on Chronic Vasospasm Hirotoshi Sano, Motoi Shoda, Youko Kato, Kazuhiro Katada, Youichi
Clinical Study of Effect of Intrathecal Use of Alpha-tocopherol on Chronic Vasospasm Hirotoshi Sano, Motoi Shoda, Youko Kato, Kazuhiro Katada, Youichi Shinomiya and Tetsuo Kanno Department of Neurosurgery,
partial androgen deficiency in agingmalepadam lateonset hypogonadism LOH ED 3 Aging Males Symptoms scale AMS androgen androgen androgen androgen Morley JE 17 52.3 20 48.5 STAI SDS STAI TEG N A C 40 2 2
!
The 22nd Annual Meeting of the Japanese Association of Cardiac Rehabilitation ! The 22nd Annual Meeting of the Japanese Association of Cardiac Rehabilitation The 22nd Annual Meeting of the Japanese Association
606 Dementia Japan Vol. 29 No. 4 October 2015 Table 1. The day care for people with severe dementia Outline Subjects Personal distribution Medical man
Dementia Japan 29 : 605-614, 2015 605 原著 要旨 1. はじめに 1 26 4.2 80 2 3 A survey of daycare facilities for dementia people in Japan Tohmi Osaki, Kiyoshi Maeda 1 650-0017 7-5 - 2 Medical Center for Dementia,
慢性膵炎
- - 121 , g CCK g g - kgkcal kgkcal - g,,, - G.I.Res ; 10 : - ; 13 : - ; 22 : - Meier RF, Beglinger C. Nutrition in pancreatic diseases. Best Pract Res Clin Gastroenterol ; 20 : - Pfutzer RH, Schneider
118 Dementia Japan Vol. 31 No. 1 January 2017 表 1. DLB に対して mect を行った先行研究 Rasmussen K 2003 USA Japan Japan Japan Japan 1 2
Dementia Japan 31 : 117-124, 2017 117 症例報告 要旨 1. はじめに 70 1 modified electroconvulsive therapy ; mect mect Modified electroconvulsive therapy in dementia with Lewy bodies with drug - resistant psychiatric
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
審査報告書（案）
19 83 7 18 628 1 19 8 3 7 18 6 28 30 MI 31 360 21700BZY00247000 5mm CEA 59 mm 2 50% 80 1. 2. 3 19 8 3 [ ] 7 [ ] [ ] [ ] [ ] 18 6 28 [ ] CEA 49mm 50 80 2 4 carotid endarterectomy CEA 1,2 CEA ECST 3 NASCET
200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,
Vol.0 No. 0 図 Montreal Cognitive AssessmentMoCA orientation visuospatial attention orientation 4 visuospatial executive MMSE MoCA language language me
Parkinson 病の認知機能障害を MMSE と MoCA により評価した多施設共同研究 : 慶應 PD データベース Cognitive impairment in Parkinson s disease patients evaluated by the Montreal Cognitive Assessment and the Mini-Mental State Examination.
16,,, 38, (1990) 17 J Toxicol Sci, 15 (Suppl IV), (1990) 18 Cognitive enhancers ( ), 13, (1990) ,, 120, (1991) 20,
1974 1,, 25, 1385-1391 (1974) 1983 2,, 34, 1451-1454 (1983) 1984 3,, Phencyclidine (PCP),, 4, 133-147 (1984) 1985 4,,,, 11, 132-146 (1985) 1986 5 Phencyclidine Angel Dust, 138, 178-180 (1986) 6, 6, 660-666
Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents
D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)
et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology
37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the
13122052_14山口.indd
108 Dementia Japan 28 : 108-115, 2014 原 著 要 旨 Key Words : 44 79.8±6.7 MMSE 1 : 44 16 4 20 11 28 47.87±27.0 16.2±3.5 mg 21 18 mg 2 : 5 MMSE 20 18.0±6.6 26.1±19.9 20.2±6.2 p=0.022 3 5 Rivastigmine transdermal
Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,
評論・社会科学 ８５号（よこ）（Ｐ）／３．佐分
well-being well-being well-being well-being QOL well-being satisfaction appraisal 69 well-being 2025 520 http : //www.mhlw.go.jp/ 2000 2004 2005 well-being 1 Walker 1996 ; Picot 1997 2003 2004 Zarit 1980
The Heart Healthy Tocotrienol Complex Tocomin SupraBio
The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio 1. Fact Sheet No. 317; World Health Organization (WHO), 2007 2. LLOYD-JONES D. et al. Circulation
教室業績2014
p- p- p- p- : - N-N : - : - : - - : - : - : - : - Katakami H, Hashida S, Oki Y, Murakami O, Ikenoue T, Ono H, Matsukura S Clin Pediatr Endocrinol, suppl : -,. Ochiai H, Ikeda T, Mishima K, Yoshikawa T,
....
2030 2 Vol. 22 No. 32000 1/2 EE F FAF 60E 1970 40 25FIP 1995 503cx 60 10M5 Vol. 22 No. 32000 3 carpal tunnel syndrome entrapment neuropathy cm 4 Vol. 22 No. 32000 5 Vol. 22 No. 32000 10 2- microglobulin
JPドメイン名レジストリレポート 2013
2013.1-12 Registry Report Registry Report Index 03 06 19 21 02 22 23 24 25 26 27 28 29 31 34 35 36 Registry Report 01 02 Registry Report Registry Report 03 04 Registry Report Registry Report 05 06 Registry
原 著 - MMSE - J Key words : MMSE - J ADNI - - MMSE - J 2006 Japanese Altzheimer s Disease Neuroimaging Initiative J - ADNI J - ADNI 2 14
原 著 MMSE J 1 2 3 Key words : MMSE J ADNI MMSE J 2006 Japanese Altzheimer s Disease Neuroimaging Initiative J ADNI 313 2010 J ADNI 2 145 6 JADNI 2010 2012 3 J ADNI 2014 3 105 68 37 2014 6 20 2010 2014 6
[4], [5] [6] [7] [7], [8] [9] 70 [3] 85 40% [10] Snowdon 50 [5] Kemper [3] 2.2 [11], [12], [13] [14] [15] [16]
![[4], [5] [6] [7] [7], [8] [9] 70 [3] 85 40% [10] Snowdon 50 [5] Kemper [3] 2.2 [11], [12], [13] [14] [15] [16]](/thumbs/93/113784833.jpg "[4], [5] [6] [7] [7], [8] [9] 70 [3] 85 40% [10] Snowdon 50 [5] Kemper [3] 2.2 [11], [12], [13] [14] [15] [16]")
1,a) 1 2 1 12 1 2Type Token 2 1 2 1. 2013 25.1% *1 2012 8 2010 II *2 *3 280 2025 323 65 9.3% *4 10 18 64 47.6 1 Center for the Promotion of Interdisciplinary Education and Research, Kyoto University 2
untitled
( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m
) 5 Lawton QOL 4 4 QOL Lawton 4) Philadelphia Geriatric Center Affect Rating ScaleARS ARS QOL 5) HDS R
Vol. 12 No. 2 2002 389 397 Λ1 Λ2 16 10 30 1 2 Lawton Philadelphia Geriatric Center Affect Rating ScaleARS Lawton ARS + ARS 6 2 ARS 2 12:00 15:0017:00 11:30 16:00 1 2 ARS 1 2 ARS QOL QOL QOL 1) QOL QOL
_02.indd
30, 11-16, 2010 Z Z score Computed tomography ROC analysis 3 CT 1,2 CT 1/3 3 5 CT CT 6 7,8 MCA ASPECTS Alberta Stroke Programme Early CT Score 4 10 CT ASPECTS 50% 9 Z 10 CT Z CT 10 Z Z Z receiver operating
2/7 徳永誠 他 :FIM 利得 退院時 FIM の予測式 表 1. 全国調査と比較した対象患者 1,118 例の基本属性データ,, FIM. FIM.. FIM.. FIM FIM.. FIM.. FIM FIM.. FIM.. FIM Functional Independenc
1/7 Japanese Journal of Comprehensive Rehabilitation Science (2015) Original Article FIM 利得および退院時 FIM の予測式 入院時 FIM, 年齢, 認知機能および転院時期で層別化した場合の FIM 利得中央値を使った手法 徳永誠, 1 三宮克彦, 1 中島雪彦, 1 野尻晋一, 1 時里香, 1 桂賢一, 1
21 1 503604705 MRI CT 1 3 MRIMRS 5 5 5 5 5 6 7 8 17 1 17 2 17 3 17 4 18 5 19 21 1 23 2 1 27 3 2 48 4 3 88 5 105 6 110 7 118 MRS MRS ATP 312CT 65 60 1 2 1 1 1 2 1 2 2 X CT MRS 3 36657269 MRIMRS 1.5TMRSymphony
8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio
7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine
2007 Vol.56 No.6 総説 丸山浩樹
Reprinted from RADIOISOTOPES, Vol.56,.6 June 2007 Japan Radioisotope Association http : //www.jrias.or.jp/ α β α β ε m z α µ µ α m z m z µ µ Curr. Opin. Biotechnol J. Proteome Res Rapid Commun. Mass
表3_学会報告記録.indd
112 113 2 1 21 1 31 1 207 21 6 27 plastic bronchitis 1 207 21 6 27 1 207 21 6 27 QT 1 208 21 11 7 1 1 208 21 11 7 B19 1 41 21 11 15 6 21 3 7 3 22 21 3 21 157 21 6 13 6 157 21 6 13 DCIS over diagnosis 2
ライフサイエンス関連 コラーゲン・ゼラチン製品案内 2015.12
3 mg/ml ph 3 4 8 1 Type I-A Type I-P Type I-A Type I-C Type III Type III Type IV Type IV TEL 072-820-3079 FAX 072-820-3095 4 8 4 Type I-A 20mL 1 F-12 MEM 5mL 1 4mL 5 10F-12MEM DFDME F-12 1 1199 5 DMERPMI-1640
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Journal Physiology, American Journal of Physiology, Journal of Physiology, Journal of Autonomic Nervous System, American Journal of Physiology,
教室業績2014
MFICU MFICU : - : - : -,,, : - : -- - : - : - : - - - : - - - - : - : - : - : -, : - Takano Y, Furukawa S, Ohashi M, Michikata K, Sameshima H, Ikenoue T J Obstet Gynaecol Res, : -, CTG - CTG - : - Katsuragi
mg 8 mg X Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD
31 1 15 20 2016 15 3 65 5 mg 8 mg 10 15 201X 7 1 11 15 Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD AKI HD 2004 48 Acute Kidney Injury AKI 48 Cr 0.3 mg/dl
21-07_後藤論文.smd
2015; 21: 5866 Yoichi Goto: Current status and future perspective of cardiac rehabilitation in Japan. J Jpn Coron Assoc 2015; 21: 5866 I 1 1 3 1 2 3 QOL 2 Fig. 1 1 196070 AMI AMI 1980 AMI CABG comprehensive
Vol.21 No AD Japanese-ADNI J-ADNI 2015 AMED AD NA-ADNI 400 AD AD 2. NA-ADNI 研究の主な成果 NA-ADNI 2004 NA-ADNI ADNI, ADNI-GO ADNI-2 phase
アルツハイマー型認知症のバイオマーカーの現状と課題 Biochemical biomarkers for Alzheimer s disease: present status and awaiting solution 京都府立医科大学分子脳病態解析学 / 教授 * 1. はじめに 460 65 10 1 85 3 1 Alzheimer s disease AD 5 7 2500 AD 460
40_01総説.indd
814-0180 8-19-1 Effect of Yokukansan on sleep disturbance in a rat model of cerebrovascular dementia Masaki Nagao Dept. Neuropharmacol. Fukuoka Univ. Sch. Pharm. Sci. 8-19- 1 Nanakuma, Jonanku, Fukuoka
1 5 6 2 3 7 8 4 5 9 10 6 7 11 12 8 1 2 3 4 5 6 7 1989 25.0% 19901999 6 2000 15.0% 9 13 1 2 3 4 5 50 2 5180 45.0% 81 35.0%, 5.0% + +, 5.0% +, 1, 5 +, 3 14 10 0% 20% 40% 60% 80% 100% n=20 3 5 2 n=20 55.0%
125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9
32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5
日本皮膚科学会第121巻第9号
Appl Nurs Res Wound Repair Regen Int Wound J Adv Skin Wound Care Ostomy Wound Manage Wound Repair Regen Int J Nurs Stud JAdvNurs Visual Dermatology J Adv Nurs Appl Nurs Res Cochrane Database Syst Rev
明海大学歯学雑誌 ３７‐２／１．秦泉寺
J Meikai Dent Med 37, 153 158, 8 153 1 7 5ml /1 min Wong-Baker Face Rating Scale FS 5 1 9. g 3 5ml /1 min, FS 1 66 6ml /1 min FS 5 1 9. g 3 6ml /1 min, FS 3 Two Cases of Xerostomia that Showed an Improvement
2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
好酸球性副鼻腔炎:診断ガイドライン（JESREC Study）
118 728 2015 : : JESREC Study Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis Study : JESREC Study CT NSAIDs CT : JESREC Study JESREC Study 118 729 ph CTMRI Caldwell Luc
29 IL-6 IL-6 PD PD MT PTOT PD Hoehn- Yahr 5 PT OT 40 5 MT MT UPDRS FIM CASMTCL FIM UPDRS 2 3 CAS MTCL MT PT OT PD
Jpn J Rehabil Med 2011 ; : 134.142 2010 9 11 IL- Myokine Myokine 1 IL 6 10 10 IL-6 40 20 40 60 IL-6 1.39 1.01 pg ml 20 2.23 1.71 pg ml 40 2.51 2.29 pg ml 60 0.63 0.59 pg ml 0.7 0.64 pg ml 0.72 0.55 pg
AD-5423_2
/ 2 /2.7 /CTD 8 8 II II 1 2 6 mg/ 6 mg/ HIV C 80 mmhg 3 1 3 80 mmhg 31 / 2 /2.7 /CTD 8 8 II II 1 2 3 23 32 / 2 /2.7 /CTD 2.7.3.3.1-28 123 2.7.3.3.1-2 8 1 2 3 2.7.3.3.1-3 2.7.3.3.1-48 2.7.3.3.1-5 40 5 7
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
Audiology Japan 45, 2002
Audiology Japan 45, 2002 Audiology Japan 45, 2002 Audiology Japan 45, 2002 Audiology Japan 45, 2002 Audiology Japan 45, 2002 12 Audiology Japan 45, 2002 14 Audiology Japan 45, 2002 16 Audiology
第124回日本医学会シンポジウム
III γ γ γ α γ Molecular Mechanism of Insulin Resistance by Adipocytes TAKASHI KADOWAKI Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo Key words γ 110 124 TNFα FFA 1,2
2012 Vol. 23 No pseudothrombophlebitis pseudothrombophlebitis
pseudothrombophlebitis 5 424 163 38.1 26 6.1 5 1.2 230 2 3 66.4 51 80 2 3 2 2 1 2012 23 3 261-265 pseudothrombophlebitis 1 2011 7 11 30 2010 2 5 47 Fig. 1 Ultrasonography showed a low echoic cyst in the
Table 1 Laboratory findings on admission Figure 2. Clinical course after admission 1-a 1-b 1-c 3-a 3-b 3-c Figure 1. CT findings on first admission: S
FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF Vol. 32, pp. 105 110, 2004 FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF 1 1 1 1 1 1 1 1 2 2 1 1 16 4 13 72 CRP
437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
% 80% BNP 80 pg/ml FIM115 Barthel Index, BI85 1 FIM BI COPD LVPSLung volume reduction surgery COPD DPB Medical Research Council Scale 2
1 1 1 PT 2 6 1 3 PT 2 OT 2 PT OT 2 1 PT 1 PT OT 2 2 1 PT 5 OT 3 ST ST 1 10 ST 1 3 30 m 2 25 m 2 100 m 2 45 m 2 100 m 2 160 m 2 45 m 2 8 m 2 8 m 2 1 PT 1 1 PT OT 1 1 PT OT 1 1 PT 1 OT 1 ST 1 PTOTST 4 1
Special IssueTo save our life from myocardial infarction -what can we do before and after heart attack- Reviews Originals Case reports et al et al et al et al et al et al et al et al et al et al et
表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
C/NC : committed/noncommitted
C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a
1 2 D- D- 1206 D- D- -2003 120 /2004 D-FDA GRAS D D- 3 5 5 D- 75 10g/kg 14 40 20 D-101520 90 1520 20%101520 1520 D- 5(D- 2300-6700mg//) () 2024 615 D- 41220g/kg/ 1220g/kg/ 20g/kg/ 1220g/kg/ () 50 D- 10%
sick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
障害者職域拡大カリキュラム研究会中間報告書構成案
3 4 5 5 7 7 9 () 9 ()23 34 1 36 47 49 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ADL QOL 36 37 38 39 40 41 42 43 44 45 46 16 8 () 19 ( ) () 21 () 47 16
92 adenocarcinoma SE ly2 v2 n0 pstage KRAS XX XX 2 1 mfolfox6 l-lv 300 / L-OHP 130 / 5-FU 600 / 5-FU 3,600 / FU/LV de Gramont
92 91 95 2016 5-FU 1 1) 2) 3) 2) 2016 1 5 2016 3 4 FOLFIRI Bevacizumab Bev 5-FU NH3 1 NH 3 5-FU NH 3 Key words: 5-FU : NH 3 orotate phosphorylase OPRT thymidylate synthase TS dihydropyrimidine dehydrogenase
AUTONOMIC FUNCTIONAL STATE IN RENAL TUBERCULOSIS REPORT III. SERUM CHOLINESTERASE ACTIVITY IN RENAL TUBERCULOSIS Sanai Yamamura The Department of Urol
AUTONOMIC FUNCTIONAL STATE IN RENAL TUBERCULOSIS REPORT III. SERUM CHOLINESTERASE ACTIVITY IN RENAL TUBERCULOSIS Sanai Yamamura The Department of Urology, Kumamoto University College of Medicine (Director:
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
日本皮膚科学会雑誌第120巻第5号
1 2 3 4 5 6 A B 1 2 α β 3 表 1 ClinicalQuestion CQ1 男性型脱毛症にミノキシジルの外用は有用か? (CQ1.1) 男性の男性型脱毛症 (CQ1.2) 女性の男性型脱毛症 CQ2 男性型脱毛症に塩化カルプロニウムの外用は有用か? CQ3 男性型脱毛症に医薬部外品 化粧品の育毛剤の外用は有用か? CQ3.1t- フラバノン CQ3.2 アデノシン CQ3.3
1 Case report 後硬膜動脈から延髄外側への穿通枝を認めた 1 例 A case of Lateral medullary artery arise from the Posterior meningeal artery 伊藤真史 泉孝嗣 西堀正洋 今井資 玉利洋介 塚田哲也 石田衛 クロ
1 Case report 後硬膜動脈から延髄外側への穿通枝を認めた 1 例 A case of Lateral medullary artery arise from the Posterior meningeal artery 伊藤真史 泉孝嗣 西堀正洋 今井資 玉利洋介 塚田哲也 石田衛 クロップ明日香 若 林俊彦 Masashi I, Takashi I, Nishihori M, Tasuku
untitled
2303 16 2 9 1 14 5 31 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2) 1487.47 11 2 1 4 104 2 14 5 31 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) 4. 1 2 1
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
”Лï‡Æ™²“¸_‚æ4“ƒ__‘dflÅPDF‘‚‡«‘o‡µ.pdf
No.4 1 1 2 No.4 No.4 2 3 4 5 6 No.4 7 8 9 No.4 10 3 No.4 No.4 4 No.4 No.4 1 2 3 4 5 6 7 8 9 10 Assessment Class and Conformity: A Study in Values, With a Reassessment Research in Social Stratification
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
日本消化器外科学会雑誌第29巻第9号
Table 1 Oligonucleotide primers used for RT-PCR and internal probes used for Southern blot hybridization Cytokine Primer Sequence (5'-3') 5' 3' Internal probe s' 3' Internal probe 5' 3' Internal probe
精神障害者
13 ACT 156-8585 2-1-8 TEL03-3304-5701 14 10 30 ACTassertive community treatment 1 ACT ACT ACT ACT Fidelity ScaleACT ACT ACT ACT ACT Fidelity 2000, 2001; 1994 Tessler & Gamache 2000 14 1 2002 1986 1994
本文／研究業績一覧
pp Annual Review pp pp pp pp PASSPORT TO STOP SMOKING pp PP pp pp pp pp pp pp P pp pp pp pp pp pp pp pp pp pp pp pp pp pp pp pppp pp pp pp Yamanaka, Margaret, Patricia Parker: English for Nurses pp pp
財団法人 在宅医療助成 勇美記念財団
( 財 ) 在宅医療助成勇美記念財団 2009( 平成 21) 年度在宅医療助成完了報告書 軽度認知障害 (MCI) における Quality of Life(QOL) の特徴と関連要因について 申請者名 : 辰巳寛所属機関 : 愛知学院大学心身科学部職名 ; 講師所属機関所在地 : 愛知県日進市岩崎町阿良池 12 提出年月日 : 平成 22 年 8 月 27 日 共同研究者 : 山本正彦 ( 愛知学院大学心身科学部
QOL 02 QOL QOL UI AI EAThoracotomy TTThoracoscopy TS QOL EA type-c y score UI 3 AI 8 School score QOL score 12
54 1 2018 2 4-1 OK-432 1 15 14 15 US CT MRI 17 cm 0.16 g/kg/day OK-432 3 1 ke 2 2 ke 3 1 1,150 ml 13 US OK-432 4-2 TJ-28 TJ-28 2003 3 2017 6 250 TJ-28 44 16 28 TJ-28 7 2 46 8.5 2 2 9 34 79.1 10 23.3 34
Imamura, 200827-30 4-8 20 C Imamura, 2008 TRPM8 Chen, 2009; Zhang, 2012Chen, 2009 Noguchi, 2013) Yamagishi, 2013 1 TRPM8 C Imamura, 2013 Zhang,2006; Imamura, 2008 ATP Imamura, 2009 C C Imamura, 2013 BNP
ケイセントラ_製品情報概要_H1-4_収載_新発売
DIC 135-627 12 CONTENTS 34 32 33 1 2 K 34 3 4 5 12 12 18 24 3 31 31 31 33 KVKA K K VKA VKA K - PT-INR KC S 1996VKA VKA 3 KK CS 33 34 35 35 35 36 36 K 32 33 213 4VKA 12VKAFDA Kcentra 42 217 1 in vitro 1
untitled
47-54 2012 1 1 1 1 1 2 1 2 10 59 1 2 1 5 2 5 10 2 10 4 484 113 42 14 4 Key words Rheumatoid Arthritis Property of the Pain Daily Life Treatment Approaches Process of Acceptance Received June 23, 2011;
flF™m…−…n„Efic’æ’¶
44 2006 Cognitive Rehabilitation by means of Personal Computer for Cerebrovascular Disease Patients with Attentional Disorders 1 1 2 2 5 4 1 PC ABA design 4 PASATTMT Ponsford PC SAS working memoryattention
5 CSF 6 CSF 7 CSF CSF CDV CDV GFAP CSF Pandy test NSE MBP LDH mu/ml 0-5 /µl AST mu/ml CK mu/ml <25 mg/dl<45 mg/dl GLU
CT MRI CSFCSF CSF CSF CSF CSF CSF (cisternal puncture) CSF 20-23G 90 (20-23G) : CSF
_06.indd
30, 35-39, 2010 0.15% 1 C 40 20 1 cm 5 mm WBC 9,400, RBC 259 10 4, Hb 8.5 g/dl, Ht 25.5%, Plt 29 10 4, BUN 116 mg/dl, Cr 7.9 mg/dl, 125 mg/dl, HbA1c 4.3%, ft3 1.97 pg/ml, ft4 1.05 ng/dl, TSH 1.09 μiu/ml,
日本皮膚科学会雑誌第122巻第2号
J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot
Juntendo Medical Journal
The hair growth effect of minoxidil Susumu OTOMO, Ph. D. Key words : minoxidil, minoxidil sulfate, hair growth, K+-channel opener, male pattern baldness Dept. of Pharmacology, Research Center Taisho Pharmaceutical
/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1
11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1